Amino Acid Nutrition for Critical Illness
(AA-ICU Trial)
Trial Summary
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the idea that Amino Acid Nutrition for Critical Illness is an effective treatment?
The available research does not provide any data specifically supporting the effectiveness of Amino Acid Nutrition for Critical Illness. The studies mentioned focus on other treatments and drugs, such as antibiotics and their dosing in critically ill children, rather than on Amino Acid Nutrition.12345
What safety data exists for amino acid nutrition in critical illness?
The safety data for amino acid nutrition in critical illness is limited. Some studies have reported severe side effects with parenteral nutrition containing amino acids, fat emulsion, and glucose. However, these studies primarily focus on the lipid component rather than amino acids specifically. Alternative lipid emulsions, such as olive oil-based formulations, have shown a better safety profile compared to soybean oil-based emulsions, but further research is needed to determine the safety of amino acid components in these formulations.678910
Is Peptamen 1.5%, Prosol 20% IV a promising treatment for critical illness?
What is the purpose of this trial?
Enhancing the anabolic effect of nutrition in critically ill patients by administering exogenous amino acids.
Research Team
Arnold S Kristof, MDCM, FRCPC
Principal Investigator
McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria
This trial is for adults over 18 who are critically ill, on mechanical ventilation in the ICU, and expected to need intensive care for at least three more days. It's not suitable for those with conditions that might interfere with the study or pose extra risks.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intravenous amino acids and enteral feeding to assess protein metabolism and anabolic processes
Follow-up
Participants are monitored for safety, effectiveness, and secondary outcomes such as mortality and hospital-acquired infections
Treatment Details
Interventions
- Peptamen 1.5%
- Prosol 20% IV
Peptamen 1.5% is already approved in United States, European Union for the following indications:
- Malabsorption
- Short bowel syndrome
- Chronic diarrhea
- Cystic fibrosis
- Malnutrition
- Cerebral palsy
- Crohn's disease
- Impaired GI function
- Malabsorption
- Short bowel syndrome
- Chronic diarrhea
- Cystic fibrosis
- Malnutrition
- Cerebral palsy
- Crohn's disease
Find a Clinic Near You
Who Is Running the Clinical Trial?
Arnold Kristof
Lead Sponsor